D. E. Shaw & Co., Inc. Macrogenics Inc Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Macrogenics Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 119,029 shares of MGNX stock, worth $384,463. This represents 0.0% of its overall portfolio holdings.

Number of Shares

119,029

Holding current value

$384,463

% of portfolio

0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.0 - $5.55 $14,907 - $27,577	4,969 Added 4.36%	119,029 $391,000
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $377,538 - $2.11 Million	114,060 New	114,060 $484,000
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $281,043 - $458,673	-60,832 Reduced 40.14%	90,723 $485,000
Q1 2023 May 15, 2023	SELL	$4.82 - $7.24 $1.65 Million - $2.48 Million	-342,372 Reduced 69.32%	151,555 $1.09 Million
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $289,330 - $604,649	-86,626 Reduced 14.92%	493,927 $3.31 Million
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $797,951 - $1.38 Million	-265,100 Reduced 31.35%	580,553 $2.01 Million
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $1.36 Million - $6.04 Million	605,055 Added 251.48%	845,653 $2.5 Million
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $1.47 Million - $3.06 Million	181,203 Added 305.08%	240,598 $2.12 Million
Q4 2021 Feb 14, 2022	SELL	$15.91 - $21.88 $307,333 - $422,655	-19,317 Reduced 24.54%	59,395 $953,000
Q3 2021 Nov 15, 2021	SELL	$19.74 - $28.7 $965,917 - $1.4 Million	-48,932 Reduced 38.33%	78,712 $1.65 Million
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $4.81 Million - $8.36 Million	-234,773 Reduced 64.78%	127,644 $3.43 Million
Q1 2021 May 17, 2021	SELL	$18.99 - $33.2 $3.89 Million - $6.81 Million	-204,987 Reduced 36.13%	362,417 $11.5 Million
Q4 2020 Feb 16, 2021	SELL	$19.41 - $26.0 $3.15 Million - $4.21 Million	-162,060 Reduced 22.22%	567,404 $13 Million
Q3 2020 Nov 16, 2020	SELL	$24.69 - $31.6 $3.09 Million - $3.96 Million	-125,188 Reduced 14.65%	729,464 $18.4 Million
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $2.31 Million - $12.9 Million	444,300 Added 108.27%	854,652 $23.9 Million
Q1 2020 May 15, 2020	SELL	$4.28 - $12.11 $850,864 - $2.41 Million	-198,800 Reduced 32.64%	410,352 $2.39 Million
Q4 2019 Feb 14, 2020	BUY	$7.95 - $12.27 $2.86 Million - $4.41 Million	359,360 Added 143.86%	609,152 $6.63 Million
Q3 2019 Nov 14, 2019	SELL	$12.44 - $17.48 $605,156 - $850,332	-48,646 Reduced 16.3%	249,792 $3.19 Million
Q2 2019 Aug 14, 2019	SELL	$14.51 - $19.71 $5.44 Million - $7.39 Million	-374,805 Reduced 55.67%	298,438 $5.06 Million
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $7.25 Million - $16.7 Million	652,694 Added 3176.28%	673,243 $12.1 Million
Q4 2018 Feb 14, 2019	BUY	$11.75 - $21.42 $69,571 - $126,827	5,921 Added 40.48%	20,549 $261,000
Q3 2018 Nov 14, 2018	SELL	$19.26 - $23.46 $979,216 - $1.19 Million	-50,842 Reduced 77.66%	14,628 $314,000
Q2 2018 Aug 14, 2018	BUY	$19.78 - $24.67 $906,240 - $1.13 Million	45,816 Added 233.11%	65,470 $1.35 Million
Q1 2018 May 15, 2018	BUY	$18.89 - $32.46 $371,264 - $637,968	19,654 New	19,654 $494,000

Others Institutions Holding MGNX

# of Institutions

132

Shares Held

55.4M

Call Options Held

215K

Put Options Held

238K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $199M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account